Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation

NCT02799888 | Unknown Phase 2 DMC

• 1 other identifier: 307-maraviroc-001
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

HLA-mismatched unrelated donor (MMUD) and HLA-haploidentical donor (Haplo Donor) hematopoietic stem cell transplantation (HSCT) is associated with increased graft-versus-host-disease (GVHD) and impaired survival. The chemokine receptor 5 (CCR5) antagonist maraviroc has immunomodulatory properties potentially beneficial for GVHD control as it can blockade lymphocyte chemotaxis without impairing T-cell function. The aim of this study is to evaluate the safety and efficacy of maraviroc combined with standard graft-versus-host-disease prophylaxis in patients with hematologic malignancies after allogeneic stem cell transplantation from HLA-Unrelated or HLA-Mismatched Related donors. Based on the results of our previously small sample study with maraviroc combined with cyclosporine/tacrolimus and methotrexate for prophylaxis of GVHD, the investigators plan to perform the clinical trail.

Conditions

Graft-versus-host Disease; Hematopoietic Stem Cell Transplantation

Keywords

Graft-versus-host Disease; Hematopoietic Stem Cell Transplantation; Acute Leukemia; Myelodysplastic syndrome; Lymphoma

Outcome Measures

Primary Outcomes (1)

• Incidence of Acute GVHD Grades II-IV

  1 Year

Secondary Outcomes (8)

• Incidence of Acute GVHD Grades III-IV

  By day +100 post-HSCT

• Incidence of Chronic GVHD

  1 Year

• Hematologic Recovery (Neutrophils and Platelets)

  Up to day +100 post-HSCT

• Disease Relapse or Progression

  1 Year

• Incidence of Transplant-Related Mortality

  By day +100 post-HSCT

Study Arms (1)

Maraviroc + standard GVHD prophylaxis

EXPERIMENTAL

Maraviroc administration (in addition to the standard prophylaxis therapy of cyclosporine/tacrolimus and methotrexate) will start on day -2 and will end on day +30 after stem cell transplant, making the total number of days of drug administration 33 days. Maraviroc will be administered 300mg twice daily orally.

Drug: Maraviroc; Drug: Cyclosporine (in HLA-Unrelated Donor Transplantation); Drug: Tacrolimus (in HLA-Mismatched Related Donor Transplantation); Drug: Methotrexate

Interventions

Maraviroc DRUG

Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.

Also known as: Selzentry

Maraviroc + standard GVHD prophylaxis

Cyclosporine (in HLA-Unrelated Donor Transplantation) DRUG

Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.

Also known as: Sandimmune, Gengraf, Neoral

Maraviroc + standard GVHD prophylaxis

Tacrolimus (in HLA-Mismatched Related Donor Transplantation) DRUG

Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.

Also known as: Prograf®, FK506

Maraviroc + standard GVHD prophylaxis

Methotrexate DRUG

Methotrexate will be administered intravenously at a dose of 15 mg/m\^2 on day +1, and 10 mg/m\^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m\^2 IV bolus on Day +1, and 10 mg/m\^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10\^9/L.

Also known as: MTX

Maraviroc + standard GVHD prophylaxis

Eligibility Criteria

• Age: 12 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 12-65 years (patient is older than 12.0 and less than 66.0 years old)
• Patients with acute leukemia, myelodysplastic syndrome or lymphoma who scheduled to undergo allogeneic stem-cell transplantation from HLA-Unrelated or HLA-Mismatched Related donors
• Renal function: estimated creatinine clearance greater than 40 mL/minute (using the Cockcroft-Gault formula and actual body weight)
• Hepatic function: Baseline direct bilirubin, alanine aminotransferase (ALT) lower than three times the upper limit of normal
• Pulmonary disease: forced vital capacity (FVC) or forced expiratory volume at one second (FEV1) \> 40% predicted
• Cardiac ejection fraction \> 40%
• Signed informed consent

You may not qualify if:

• Patients not expected to be available for follow-up in our institution for at least 100 days after the transplant
• Prior allogeneic transplant
• Karnofsky Performance Score \< 70%
• Patients who are not undergoing standard GVHD prophylaxis with cyclosporine/tacrolimus and methotrexate
• Patients with uncontrolled bacterial, viral or fungal infections
• Patients receiving other investigational drugs for GVHD

Sponsors & Collaborators

• Affiliated Hospital to Academy of Military Medical Sciences: lead

Study Sites (1)

Department of Hematopoietic Stem Cell Transplantation

Beijing, Beijing Municipality, 100071, China

RECRUITING

MeSH Terms

Conditions

Graft vs Host Disease; Myelodysplastic Syndromes; Lymphoma

Interventions

Maraviroc; Cyclosporine; Cyclosporins; Tacrolimus; Methotrexate

Condition Hierarchy (Ancestors)

Immune System Diseases; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders

Intervention Hierarchy (Ancestors)

Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Triazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Peptides, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Peptides; Amino Acids, Peptides, and Proteins; Macrolides; Lactones; Aminopterin; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Hu Chen, M.D., Ph.D.

  Affiliated Hospital to Academy of Military Medical Sciences

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Hongmei Ning, M.D., Ph.D.

CONTACT

+86 10 66947405; ninghongmei72@sina.com

Yongfeng Su, M.D., Ph.D.

CONTACT

+86 10 66947122; suyongfeng199705@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 3, 2016
• First Posted: June 15, 2016
• Study Start: April 1, 2014
• Primary Completion: December 1, 2016
• Study Completion: April 1, 2017
• Last Updated: June 15, 2016

Record last verified: 2016-06

Locations

CN (1)